加科思-B(01167)发布公告，于2025年9月24日，该公司斥资49.72万港元回购5.25万股。 ...

智通财经APP讯，加科思-B(01167)发布公告，于2025年9月24日，该公司斥资49.72万港元回购5.25万 股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 加科思藥業集團有限公司 第 1 頁 共 6 頁 v 1.3.0 FF305 確認 不適用 第一章節註釋： 若股份曾以超過一個每股價格發行/出售/購回/贖回，則須提供每股成交量加權平均價格。 呈交日期： 2025年9月24日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01167 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | 事件 ...

Group 1 - The stock of 加科思-B (01167) increased by over 5%, reaching an 8.61% rise to 11.23 HKD with a trading volume of 117 million HKD [1] - A report from The New York Times indicates that the Trump administration is considering an executive order to limit U.S. pharmaceutical companies from acquiring innovative drugs developed in China, which could disrupt the supply chain [1] - According to Shenwan Hongyuan's research report, the likelihood of this draft being implemented is very low, emphasizing the investment value of China's innovative drug sector supported by "innovation upgrade + profit inflection point + normalization of overseas business development" [1] Group 2 - 加科思 reported a mid-term revenue of 45.664 million RMB, compared to zero revenue in the same period last year [1] - The company recorded a loss attributable to owners of 58.994 million RMB, a year-on-year reduction of 65.1% [1] - The revenue growth is primarily attributed to milestone payments from the Elysium licensing agreement [1]

根据加科思发布的中期业绩，集团期内取得4566.4万元人民币，去年同期为零收入;公司拥有人应占亏 损5899.4万元，同比收窄65.1%。公告称，收入增长主要得益于艾力斯许可协议的里程碑付款。 消息面上，《纽约时报》近日报道称，特朗普政府正在讨论一项行政命令，拟对美国制药企业收购中国 研发的创新药物设限。草案若实施，可能切断美国药企获取中国实验性药物的渠道，并加剧供应链风 险。申万宏源研报指出，该草案的落地概率极低，并再次强调了中国创新药板块的投资价值，表示"创 新升级+盈利拐点+出海BD常态化"三重逻辑支撑后续行情。 智通财经APP获悉，加科思-B(01167)涨超5%，截至发稿，涨8.61%，报11.23港元，成交额1.17亿港元。 ...

Core Viewpoint - After a significant drop, Hong Kong's innovative drug concept stocks rebounded across the board, indicating market resilience and potential recovery in the sector [1] Group 1: Market Performance - As of the report, Kangning Jereh Pharmaceutical-B surged over 14%, Hutchison China MediTech rose more than 6%, Zai Lab and Lepu Biopharma B increased over 5%, and Akeso-B climbed over 4% [1] Group 2: Industry Sentiment - Several pharmaceutical companies have acknowledged rumors regarding potential restrictions from the U.S. on innovative drugs from China, but they believe these rumors do not currently impact the expectations for Chinese innovative drugs entering international markets [1] Group 3: Future Outlook - Market analysts predict that leading biotech companies such as BeiGene and Innovent Biologics are expected to reach a profitability inflection point by 2025, with a strong growth trajectory anticipated thereafter [1] - With improvements in industrial capabilities and product line expansions, it is expected that more biotech firms will enter a profitability cycle in the future [1]

Core Viewpoint - The company, 加科思-B (01167), has seen its concerted action members purchase a total of 402,000 shares at an average price of HKD 10.16 per share, reflecting confidence in the company's growth potential and long-term investment value [1] Group 1 - The concerted action members increased their holdings to a total of 201,157,285 shares, representing approximately 25.41% of the company's total issued shares [1] - The members expressed confidence in the overall development prospects and growth potential of the company [1] - There is a possibility of further share purchases by the concerted action members, subject to applicable laws and regulations [1]

Group 1 - The company, 加科思-B (01167), announced that from September 1 to September 3, 2025, its concerted action members purchased a total of 402,000 shares at an average price of HKD 10.16 per share in the open market [1] - Following this increase in holdings, the concerted action members collectively own 201,157,285 shares, representing approximately 25.41% of the company's total issued shares [1] - The concerted action members expressed confidence in the company's overall development prospects, growth potential, and long-term investment value of its shares, indicating the possibility of further share purchases in compliance with applicable laws and regulations [1]

JACOBIO PHARMACEUTICALS GROUP CO., LTD. 加 科 思 藥 業 集 團 有 限 公 司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本公司董事會（「董事會」）已獲公司一致行動人士成員告知，於2025年9月1日至9月3日，彼 等已於公開市場按10.16港元的平均每股價格繼續買入合計402,000股本公司股份（「股份」）。 緊隨此次持股增加之後，截至本公告日期，一致行動人士共持有本公司201,157,285股股份， 約佔本公司已發行股份總數的25.41%。 上述一致行動人士成員表示對本公司的整體發展前景、增長潛力及其股份的長期投資價 值充滿信心。在遵守適用法律及監管規定的前提下，並不排除其可能適時進一步增持本 公司股份。 根據本公司所得資料及據董事會所知，本次增持已遵照適用法律、規則及條文（包括《香 港聯合交易所有限公司證券上市規則》附錄C3所載的《上市發行人董事進行證券交易的標 準守則》進行。 承董事會命 加科思 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 加科思藥業集團有限公司 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01167 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.0001 USD | | 100,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 1,000,000,000 | USD | | 0.0001 USD | | 100,000 | 本月底法定/註冊股本總額： USD 100,000 ...